An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element

Marc R. Mansour(Harvard University), Brian J. Abraham(Whitehead Institute for Biomedical Research), Lars Anders(Whitehead Institute for Biomedical Research), Alla Berezovskaya(Harvard University), Alejandro Gutiérrez(Boston Children's Hospital), Adam D. Durbin(Harvard University), Julia Etchin(Harvard University), Lee N. Lawton(Whitehead Institute for Biomedical Research), Stephen E. Sallan(Boston Children's Hospital), Lewis B. Silverman(Boston Children's Hospital), Mignon L. Loh(UCSF Benioff Children's Hospital), Stephen P. Hunger(Children's Hospital Colorado), Takaomi Sanda(National University Cancer Institute, Singapore), Richard A. Young(Whitehead Institute for Biomedical Research), A. Thomas Look(Boston Children's Hospital)
Science
November 14, 2014
Cited by 814Open Access
Full Text

Abstract

In certain human cancers, the expression of critical oncogenes is driven from large regulatory elements, called super-enhancers, that recruit much of the cell's transcriptional apparatus and are defined by extensive acetylation of histone H3 lysine 27 (H3K27ac). In a subset of T-cell acute lymphoblastic leukemia (T-ALL) cases, we found that heterozygous somatic mutations are acquired that introduce binding motifs for the MYB transcription factor in a precise noncoding site, which creates a super-enhancer upstream of the TAL1 oncogene. MYB binds to this new site and recruits its H3K27 acetylase-binding partner CBP, as well as core components of a major leukemogenic transcriptional complex that contains RUNX1, GATA-3, and TAL1 itself. Additionally, most endogenous super-enhancers found in T-ALL cells are occupied by MYB and CBP, which suggests a general role for MYB in super-enhancer initiation. Thus, this study identifies a genetic mechanism responsible for the generation of oncogenic super-enhancers in malignant cells.


Related Papers

No related papers found

Powered by citation graph analysis